RPG Life Sciences Limited reported a 15.8% year-on-year increase in consolidated revenue from operations to ₹195.7 crore for the quarter ended June 30, 2026 (Q1FY27), compared to ₹168.9 crore in Q1FY26. Consolidated profit after tax (PAT) rose 17.0% to ₹30.8 crore from ₹26.3 crore in the prior year period. The growth was driven by robust performance in domestic formulations and a significant recovery in the API segment, while EBITDA expanded 17.9% to ₹48.0 crore with margins improving to 24.5% from 24.1%.

The Board of Directors approved the unaudited standalone and consolidated financial results at a meeting held on July 28, 2026. The results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, S R B C & Co LLP, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Rajesh Shirambekar, Head-Legal & Company Secretary, signed the press release on July 28, 2026.

Financial Performance Highlights

Consolidated revenue from operations stood at ₹195.7 crore for the quarter, up from ₹168.9 crore in Q1FY26. Total income increased proportionately, with other income contributing to the overall top-line. EBITDA rose to ₹48.0 crore from ₹40.7 crore in the prior year period, reflecting improved operating leverage. Profit before tax (PBT) increased 17.0% to ₹41.5 crore from ₹35.4 crore, with PBT margin expanding slightly to 21.2% from 21.0%. Finance costs remained low, supporting the bottom-line expansion.

The following table summarises the key consolidated financial metrics for the quarter:

Standalone net profit came in at ₹306 million rupees versus ₹263 million rupees in the corresponding quarter of the previous year. Earnings per share (basic and diluted) rose to ₹18.49 from ₹15.90 in the corresponding quarter of the previous year. Consolidated EPS increased to ₹18.60 from ₹15.90. No exceptional items were recorded in Q1FY27, unlike the previous fiscal year which saw impacts from insurance claims and new labour codes.

Segmental Growth Drivers

Domestic Formulations contributed 68.3% to total sales, registering 14.8% growth to ₹132.5 crore from ₹115.4 crore in Q1FY26. This outperformed the broader Indian Pharma Market growth of 11.6%, supported by key therapy focus, new product introductions in specialty and chronic segments, and field-force effectiveness. International Formulations registered 7.7% growth to ₹35.0 crore from ₹32.5 crore, contributing 18.0% to total sales. The API business delivered 35.6% growth to ₹26.6 crore from ₹19.6 crore as units returned to operations following a fire incident in one of the manufacturing blocks during the prior year.

Key brands such as Naprosyn grew at 16%, alongside double-digit growth in nephrology and rheumatology baskets. The company is focused on scaling core brands like Naprosyn towards becoming a ₹100 crore+ brand. RPG Life Sciences also entered the coveted list of “Top 50 Pharma Companies” in India as per the Indian Pharma Market report for June 2026, advancing its ranking from 62 in March 2025 to 50 in June 2026.

What the Numbers Show

The expansion in EBITDA margin despite rising operational costs indicates effective cost management and pricing power in core therapeutic areas. The divergence between domestic formulation growth (14.8%) and market growth (11.6%) highlights RPG Life Sciences' competitive advantage in its home market. The significant recovery in the API segment suggests successful operational turnaround efforts, contributing to the overall robustness of the earnings profile. ICRA reaffirmed the long-term rating at A+ with a stable outlook, citing robust capital structure, healthy cash flows, and no debt-funded capital expenditure.

RPG Life Sciences Limited has announced the cessation of Ms. Zahabiya Khorakiwala as an Independent Director, effective July 26, 2026. The departure marks the conclusion of her second consecutive five-year term on the Board. This change triggers a reconstitution of the Sustainability and Corporate Social Responsibility Committee, altering the governance structure for environmental and social oversight within the company.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing also references compliance with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Rajesh Shirambekar, Head – Legal & Company Secretary, signed the disclosure submitted to both the National Stock Exchange of India Limited and BSE Limited on July 27, 2026.

Committee Reconstitution

Following Ms. Khorakiwala’s exit, she ceased to be a member of the Sustainability and Corporate Social Responsibility Committee. The Board reconstituted this committee effective July 27, 2026. The new composition places Ms. Radhika Gupta in the leadership role, with Mr. Sachin Nandgaonkar and Mr. Ashok Nair serving as members.

Director Details

Ms. Zahabiya Khorakiwala, identified by DIN 00102689, served her full term without incident or early resignation. The company confirmed that the reason for the change in directorship was strictly the completion of the statutory maximum tenure for independent directors under current regulations.

What the Numbers Show

The exit of an independent director after two consecutive terms is a standard regulatory requirement designed to ensure fresh perspectives on corporate governance boards. For RPG Life Sciences, this transition ensures compliance with SEBI’s norms on board rotation while maintaining continuity through the immediate reconstitution of key committees. The appointment of Ms. Radhika Gupta as Chairperson of the Sustainability and Corporate Social Responsibility Committee signals the company’s continued focus on ESG governance structures despite the personnel change.